Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Change in Acquisitions & Divestments (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Change in Acquisitions & Divestments for 10 consecutive years, with $51.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 41.0% to $51.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $252.5 million, a 3.13% decrease, with the full-year FY2025 number at $252.5 million, down 3.13% from a year prior.
  • Change in Acquisitions & Divestments was $51.6 million for Q4 2025 at Rhythm Pharmaceuticals, down from $61.5 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $156.7 million in Q3 2021 to a low of $45.3 million in Q3 2024.
  • A 5-year average of $75.7 million and a median of $66.2 million in 2021 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: plummeted 60.76% in 2022, then skyrocketed 144.12% in 2023.
  • Rhythm Pharmaceuticals' Change in Acquisitions & Divestments stood at $69.0 million in 2021, then fell by 13.63% to $59.6 million in 2022, then rose by 6.12% to $63.3 million in 2023, then surged by 38.3% to $87.5 million in 2024, then plummeted by 41.0% to $51.6 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Change in Acquisitions & Divestments are $51.6 million (Q4 2025), $61.5 million (Q3 2025), and $81.0 million (Q2 2025).